| Persistent hypogammaglobulinemia (n=5) | No persistent hypogammaglobulinemia (n=11) | |
|---|---|---|
| M:F | 4:1 | 10:1 |
| Malignant/Non-malignant | 5/0 | 6/5 |
| HLA Matched/Mismatch | 4/1 | 7/4 |
| T cell depleted/ Unmodified | 4/1 | 11/0 |
| Median time frame from HCT to rituximab in days (range) | 82 (33-193) | 84 (57-117) |
| Median number of doses of rituximab (range) | 6 (2-6) | 4 (2-6) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.